DSM Buys Stake in Antibody Firm

DSM Venturing, the venture capital arm of DSM, says it has made an equity investment in biotech firm IQ Therapeutics (Groningen, the Netherlands), a developer of antibodies for vaccines. DSM says it holds a“significant minority share in the business,” although financial terms were not disclosed. IQ Therapeutics’ portfolio includes an anti-anthrax vaccine, a product with “great potential,” says Karen King, president, DSM...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers